Fuhong Hanjun Adamu single anti-new adaptive disorder was approved

Adamo monoanti-resistant monoclonal antibody biosypolytic drug developed independently for Fuhong Hanyu was approved for listing in China (excluding Hong Kong, Macao and Taiwan) in December 2020, and the approved adaptations were psoriasis, rheumatoid arthritis, and severe spina bifida.
this time to the State Drug Administration to apply for the relevant supplementary, mainly for the new drug to add staphylococcitis adaptation.
new drug research and development monitoring database (CPM) shows that a total of 16 Adamo single anti-injections have been approved for sale worldwide.
in the domestic market, Adamo single anti-injection mainly includes AbbVie's Shumeile, Haizheng Pharmaceuticals' AnJianning, Baiotai's Greeley and so on.
Drug Research and Development Monitoring Database (CPM) Drug Comprehensive Database (PDB) shows that the market for Adamo single-dose hospitals was weak in 2012-2019, but since entering the health insurance catalog in 2019, the market for Adamo single-dose injections has grown rapidly, with Q1-3 amounting to about 58.86 million yuan in 2020.
Comprehensive Drug Database (PDB) as of December 2020, Fuhong Hanxuan has invested approximately 270 million yuan in research and development of the new drug, including approved market-listed and staphylactics.
Adamo monoantigen is AbbVie's anti-TNF-ɑ all-human antibody, approved in the United States in 2002, more than 10 years have been approved including rheumatoid arthritis, strong straight spina bifida, plaque psoriasis, Crohn's disease, childhood idylpathic arthritis and staphylacitis and other 10 adaptations.
its annual sales for the 7th consecutive year in the world, with global sales of $20.5 billion in 2018, and the effectiveness of treatment for my own immune system diseases has been widely verified.